Publications from the MyPeBS team


Nous sommes fiers de partager ces récents articles publiés par les équipes impliquées dans le consortium MyPeBS, dans le domaine de l’évaluation et de la prévention du risque de cancer du sein.


“For and against” factors infuencing participation in personalized breast cancer screening programs: a qualitative systematic review until March 2022

Celmira Laza, Ena Niño de Guzmán, Montserrat Gea, Merideidy Plazas, Margarita Posso, Montserrat Rué, Xavier Castells and Marta Román
Archives of Public Health (2024) (2024) 82:23


Breast cancer screening in women with extremely dense breasts: recommendations of the European Society of Breast Imaging (EUSOBI).
Mann RM; Athanasiou A; Baltzer PAT; Camps-Herrero J; Clauser P; Fallenberg EM; Forrai G; Fuchsjäger MH; Helbich T; Killburn-Toppin F; Lesaru M; Panizza P; Pediconi F; Pijnappel RM; Pinker K; Sardanelli F; Sella T; Thomassin-Nagarra I; Zackrisson S; Gilbert FJ; Kuhl CK. Eur Radiol. 2022 Mar 8. doi: 10.1007/s00330-022-08617-6.

Machine Learning for workflow applications in screening mammography: Systematic review and meta-analysis.
Hickman S., Woitek R, Le EPV, Im YR, Luxhoj CM, Aviles-Rivero AI, Baxter GC, MacKay JW, Gilbert FJ. Radiology. 2022 Jan;302(1):88-104. doi: 10.1148/radiol.2021210391

Long-Term Risk of Breast Cancer after Diagnosis of Benign Breast Disease by Screening Mammography.
Román M, Louro J, Posso M, Vidal C, Bargalló X, Vázquez I, Quintana M.J, Alcántara R, Saladié F, del Riego J, Peñalva L, Sala M, Castells X, on behalf of the BELE and IRIS Study Groups. Int. J. Environ. Res. Public Health. 2022; 19(5):2625.

Mammographic features of benign breast lesions and risk of subsequent breast cancer in women attending breast cancer screening.
Posso M, Alcántara R, Vázquez I, Comerma L, Baré M, Louro J, Quintana MJ, Román M, Marcos-Gragera R, Vernet-Tomas M, Saladie F, Vidal C, Bargalló X, Peñalva L, Sala M, Castells X, BELE study group. Eur Radiol. 2022; 32:621-629. Doi: 10.1007/s00330-021-08118-y



Imaging strategy for breast cancer screening

Borcoman E, Attard M, Arfi-Rouche J, Majer M, Haddag-Miliani L, Delaloge S. Rev Prat. 2020 Sep;70(7):722-725.

Differences in breast cancer risk after benign breast disease by type of screening diagnosis.
Louro J, Román M, Posso M, Comerma L, Vidal C, Saladié F, Alcántara R, Sánchez M, Quintana MJ, del Riego J, Ferrer J, Peñalva L, Bargalló X, Prieto M, Sala M, Castells X. Breast. 2020;

Personalized early detection and prevention of breast cancer: ENVISION consensus statement.
Pashayan N et al. Nat Rev Clin Oncol. 2020 Nov;17(11):687-705. doi: 10.1038/s41571-020-0388-9. Epub 2020 Jun 18.

Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D.
Yang X, Song H, et al.  J Natl Cancer Inst. 2020 Dec 14;112(12):1242-1250. doi: 10.1093/jnci/djaa030.

A case-control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density.
Brentnall AR, et al. Int J Cancer. 2020 Apr 15;146(8):2122-2129. doi: 10.1002/ijc.32541. Epub 2019 Jul 13.

Evidence for reducing cancer-specific mortality due to screening for breast cancer in Europe: A systematic review.
Zielonke N, et al.  Eur J Cancer. 2020 Mar;127:191-206. doi: 10.1016/j.ejca.2019.12.010. Epub 2020 Jan 10.

Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.
Yang X, et al. J Clin Oncol. 2020 Mar 1;38(7):674-685. doi: 10.1200/JCO.19.01907. Epub 2019 Dec 16

Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial.
De Koning HJ, et al.  N Engl J Med. 2020 Feb 6;382(6):503-513. doi: 10.1056/NEJMoa1911793. Epub 2020 Jan 29.

Assessment of interactions between 205 breast cancer susceptibility loci and 13 established risk factors in relation to breast cancer risk, in the Breast Cancer Association Consortium.
Kapoor PM, et al. Int J Epidemiol. 2020 Feb 1;49(1):216-232. doi: 10.1093/ije/dyz193.

International evaluation of an AI system for breast cancer screening.
McKinney SM, et al.  Nature. 2020 Jan;577(7788):89-94. doi: 10.1038/s41586-019-1799-6. Epub 2020 Jan 1.

Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
Cuzick J, et al. Lancet. 2020 Jan 11;395(10218):117-122. doi: 10.1016/S0140-6736(19)32955-1. Epub 2019 Dec 12.

Improving Workflow Efficiency for Mammography Using Machine Learning.
Kyono T, Gilbert FJ, van der Schaar M. J Am Coll Radiol. 2020 Jan;17(1 Pt A):56-63. doi: 10.1016/j.jacr.2019.05.012. Epub 2019 May 30.

New evidence confirms that reproductive risk factors can be used to stratify breast cancer risks: Implications for a new population screening paradigm.
Evans DG, Howell SJ, Howell A. Eur J Cancer. 2020 Jan;124:204-206. doi: 10.1016/j.ejca.2019.10.012. Epub 2019 Nov 26.

Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis.
Papadimitriou, et al.  Nat Commun. 2020 Jan 30;11(1):597. doi: 10.1038/s41467-020-14389-8.

Breast cancer risk status influences uptake, retention and efficacy of a weight loss programme amongst breast cancer screening attendees: two randomised controlled feasibility trials.
Harvie M, et al. BMC Cancer. 2019 Dec 4;19(1):1089. doi: 10.1186/s12885-019-6279-8.

Artificial intelligence and breast screening: French Radiology Community position paper.
Thomassin-Naggara I, Balleyguier C, Ceugnart L, et al. Diagn Interv Imaging. 2019 Oct;100(10):553-566. doi: 10.1016/j.diii.2019.08.005. Epub 2019 Sep 12.

All-cause mortality versus cancer-specific mortality as outcome in cancer screening trials: A review and modeling study.
Heijnsdijk EAM, et al. Cancer Med. 2019 Oct;8(13):6127-6138. doi: 10.1002/cam4.2476. Epub 2019 Aug 18.

Predicting Breast Cancer by Applying Deep Learning to Linked Health Records and Mammograms.
Akselrod-Ballin A, et al. Radiology. 2019 Aug;292(2):331-342. doi: 10.1148/radiol.2019182622. Epub 2019 Jun 18.

Methods for Development of the European Commission Initiative on Breast Cancer Guidelines: Recommendations in the Era of Guideline Transparency.
Schünemann HJ et al. Ann Intern Med. 2019 Aug 20;171(4):273-280. doi: 10.7326/M18-3445. Epub 2019 Jul 23.


Validation of a new fully automated software for 2D digital mammographic breast density evaluation in prediction of breast cancer: a multicentre study.
Rossi PG; Djuric O; Hélin V; Astley S; Mantellini P; Nitrosi A; Harkness EF; Gauthier E; Puliti D; Balleyguier C; Baron C; Gilbert FJ; Grivegnée A; Pattacini P; Michiels S; Delaloge S. Sci Rep. 2021 Oct 6;11(1):19884. doi: 10.1038/s41598-021-99433-3.

Breast density, benign breast disease, and risk of breast cancer over time.
Román M, Louro J, Posso M, Alcántara R, Peñalva L, Sala M, Del Riego J, Prieto M, Vidal C, Sánchez M, Bargalló X, Tusquets I, Castells X, on behalf of the BELE and IRIS study groups. Eur Radiol. 2021. doi: 10.1007/s00330-020-07490-5. PMID: 33409776.

Developing and validating an individualized breast cancer risk prediction model for women attending breast cancer screening.
Louro J, Román M, Posso M, Vázquez I, Saladié F, Rodriguez-Arana A, Quintana MJ, Domingo L, Baré M, Marcos-Gragera R, Vernet-Tomas M, Sala M, Castells X, and BELE and IRIS Study Groups. PLoS ONE. 2021, 16(3): e0248930.

Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History.

van den Broek JJ, Schechter CB, van Ravesteyn NT, Janssens ACJW, Wolfson MC, Trentham-Dietz A, Simard J, Easton DF, Mandelblatt JS, Kraft P, de Koning HJ.J Natl Cancer Inst. 2021 Apr 6;113(4):434-442. doi: 10.1093/jnci/djaa127.PMID: 32853342

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga JY, Bermejo B, Ramos-Vazquez M, Jung KH, Ferrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Pusztai L, Hortobagyi GN. N Engl J Med. 2021 Dec 16;385(25):2336-2347. doi: 10.1056/NEJMoa2108873.

Multicenter evaluation of breast cancer patients’ satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic.
Bizot A, Karimi M, Rassy E, Heudel PE, Levy C, Vanlemmens L, Uzan C, Deluche E, Genet D, Saghatchian M, Giacchetti S, Grenier J, Patsouris A, Dieras V, Pierga JY, Petit T, Ladoire S, Jacot W, Benderra MA, De Jesus A, Delaloge S, Lambertini M, Pistilli B. Br J Cancer. 2021 Sep 29. doi: 10.1038/s41416-021-01555-y

Therapeutic vaccines for breast cancer: Has the time finally come?
Corti C, Giachetti PPMB, Eggermont AMM, Delaloge S, Curigliano G.Eur J Cancer. 2021 Nov 22:S0959-8049(21)01185-0

Surgery or not on an atypical breast lesion? Taking anxiety into account in shared decision support from a prospective cohort of 300 patients.
Favier A, Boinon D, Salviat F, Mazouni C, Korvin B, Tunon C, Salomon AV, Doutriaux-Dumoulin I, Vaysse C, Marchal F, Boulanger L, Chabbert-Buffet N, Zilberman S, Coutant C, Espié M, Cortet M, Boussion V, Cohen M, Fermeaux V, Mathelin C, Michiels S, Delaloge S, Uzan C, Charles C. Gynecol Obstet Fertil Senol. 2021 Sep 22:S2468-7189(21)00220-8.

Impact of COVID-19 on healthcare organisation and cancer outcomes.
Bardet A, Fraslin AM, Marghadi J, Borget I, Faron M, Honoré C, Delaloge S, Albiges L, Planchard D, Ducreux M, Hadoux J, Colomba E, Robert C, Bouhir S, Massard C, Micol JB, Ter-Minassian L, Michiels S, Auperin A, Barlesi F, Bonastre J. Eur J Cancer. 2021 May 28;153:123-132

BRCA2: a 25-year journey from gene identification to targeted cancer treatment.
Grinda T, Delaloge S. Lancet Oncol. 2021 Jun;22(6):763-764.

Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment.
Terrisse S, Derosa L, Iebba V, Ghiringhelli F, Vaz-Luis I, Kroemer G, Fidelle M, Christodoulidis S, Segata N, Thomas AM, Martin AL, Sirven A, Everhard S, Aprahamian F, Nirmalathasan N, Aarnoutse R, Smidt M, Ziemons J, Caldas C, Loibl S, Denkert C, Durand S, Iglesias C, Pietrantonio F, Routy B, André F, Pasolli E, Delaloge S, Zitvogel L. Cell Death Differ. 2021 May 7. doi: 10.1038/s41418-021-00784-1.

Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort.
Grinda T, Antoine A, Jacot W, Blaye C, Cottu PH, Diéras V, Dalenc F, Gonçalves A, Debled M, Patsouris A, Mouret-Reynier MA, Mailliez A, Clatot F, Levy C, Ferrero JM, Desmoulins I, Uwer L, Petit T, Jouannaud C, Lacroix-Triki M, Deluche E, Robain M, Courtinard C, Bachelot T, Brain E, Pérol D, Delaloge S. ESMO Open. 2021 Apr 22;6(3):100114.

Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort.
Grinda T, Joyon N, Lusque A, Lefèvre S, Arnould L, Penault-Llorca F, Macgrogan G, Treilleux I, Vincent-Salomon A, Haudebourg J, Maran-Gonzalez A, Charafe-Jauffret E, Courtinard C, Franchet C, Verriele V, Brain E, Tas P, Blanc-Fournier C, Leroux A, Loussouarn D, Berghian A, Brabencova E, Ghnassia JP, Scoazec JY, Delaloge S, Filleron T, Lacroix-Triki M. NPJ Breast Cancer. 2021 Apr 16;7(1):41. doi: 10.1038/s41523-021-00252-6.

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
Piccart M, van ‘t Veer LJ, Poncet C, Lopes Cardozo JMN, Delaloge S, Pierga JY, Vuylsteke P, Brain E, Vrijaldenhoven S, Neijenhuis PA, Causeret S, Smilde TJ, Viale G, Glas AM, Delorenzi M, Sotiriou C, Rubio IT, Kümmel S, Zoppoli G, Thompson AM, Matos E, Zaman K, Hilbers F, Fumagalli D, Ravdin P, Knox S, Tryfonidis K, Peric A, Meulemans B, Bogaerts J, Cardoso F, Rutgers EJT. Lancet Oncol. 2021 Mar 12:S1470-2045(21)00007-3.

A major genetic accelerator of cancer diagnosis: rs867228 in FPR1.
Sztupinszki Z, Le Naour J, Vacchelli E, Laurent-Puig P, Delaloge S, Szallasi Z, Kroemer G. Oncoimmunology. 2021 Jan 6;10(1):1859064. doi: 10.1080/2162402X.2020.1859064.

A meta-analysis comparing the diagnostic performance of abbreviated MRI and a full diagnostic protocol in breast cancer.
Baxter G, Selamoglu A, MacKay JM, Gray E, Bond S, Gilbert FJ. Clinical Radiology 2021;76:154. Doi 10.1016/j.crad.2020.08.036

Introduction of an Abbreviated Breast MRI Service in the UK as part of the BRAID Trial: Practicalities, Challenges and Future Directions.
Vinnicombe S, Harvey H, Healy NA, Papalouka V, Schiller A, Moyle P, Kilburn-Toppin F, Allajbeu I, Sharma N, Maxwell AJ, Payne N, Graves M, Gilbert FJ. Clin Radiol. 2021 Jun;76(6):427-433. doi: 10.1016/j.crad.2021.01.020. Epub 2021 Mar 9.

Adoption of artificial intelligence in breast imaging: evaluation, ethical constraints and limitations.
Hickman S, Baxter G, Gilbert FJ. British Journal of Cancer 2021;125:15-22  doi:10.1038/s41416-021-01333-w

Opportunities in Cancer Imaging: risk adapted breast imaging for screening.
Gilbert FJ, Hickman SE, Baxter GC, Allajbeu I,. Carraco C, James J, Vinnicombe S. Clin Radiol. 2021 Oct;76(10):763-773. doi: 10.1016/j.crad.2021.02.013. Epub 2021 Apr 2.

Triage of 2D Mammographic Images Using Multi-view Multi-task Convolutional Neural Networks.
Kyono T, Gilbert FJ, van der Schaar M. ACM Transactions on Computing for Healthcare 2021. doi: 10.1145/3453166

Automated breast Ultrasound: technical aspects, impact on breast screening and future perspectives.
Allajbeu I, Payne N, Hickman S, Gilbert FJ. Current Breast Cancer Reports accepted May 2021



Personalized breast cancer screening strategies: A systematic review and quality assessment.
Román M, Sala M, Domingo L, Posso M, Castells X. PLoS One. 2019; 14(12):e0226352. Doi: 10.1371/journal.pone.0226352.

A systematic review and quality assessment of individualised breast cancer risk prediction models.
Louro J, Posso M, Boon MH, Román M, Domingo L, Castells X, Sala M. Br J Cancer. 2019; doi: 10.1038/s41416-019-0476-8.

Changes in mammographic density over time and the risk of breast cancer: an observational cohort study.
Román M, Sala M, Baré M, Posso M, Vidal C, Louro J, Sánchez M, Peñalva L, Castells X, on behalf of the BELE study group. Breast. 2019; 46:108-115.

Mammographic breast density: How it affects performance indicators in screening programmes?
Posso M, Louro J, Sánchez M, Román M, Vidal C, Sala M, Baré M, Castells X; BELE study group.  Eur J Radiol. 2019; 110:81-87. doi: 10.1016/j.ejrad.2018.11.012.

Long-term risk of screen-detected and interval breast cancer after false-positive results at mammography screening: Joint analysis of three national cohorts.
Román M, Hofvind S, von Euler-Chelpin M, Castells X. Br J Cancer. 2019; 120(2):269-275. doi: 10.1038/s41416-018-0358-5.

Effect of screening mammography on breast cancer mortality: Quasi-experimental evidence from rollout of the Dutch population-based program with 17-year follow-up of a cohort.
Van Ourti T, et al. Int J Cancer. 2020 Apr 15;146(8):2201-2208. doi: 10.1002/ijc.32584. Epub 2019 Aug 7.

The influence of health systems on breast, cervical and colorectal cancer screening: an overview of systematic reviews using health systems and implementation research frameworks.
Priaulx J, et al. J Health Serv Res Policy. 2019 Jul 8:1355819619842314. doi: 10.1177/1355819619842314. [Epub ahead of print] No abstract available.

MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.
Saadatmand S, et al. FaMRIsc study group. Lancet Oncol. 2019 Aug;20(8):1136-1147. doi: 10.1016/S1470-2045(19)30275-X. Epub 2019 Jun 17.

The WISDOM Personalized Breast Cancer Screening Trial: Simulation Study to Assess Potential Bias and Analytic Approaches.
Eklund M, et al. JNCI Cancer Spectr. 2019 Jan 8;2(4):pky067.

Attitudes towards risk-stratified breast cancer screening among women in England: A cross-sectional survey.
Ghanouni A, et al. J Med Screen. 2019 Nov 8. doi: 10.1177/0969141319883662.

Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants.
Evans DGR, et al. Breast Cancer Res Treat. 2019 Apr 2. doi: 10.1007/s10549-019-05210-2. [Epub ahead of print]

Women’s perceptions of personalized risk-based breast cancer screening and prevention: An international focus group study.
Rainey L, Jervaeus A, Donnelly LS, Evans DG, Hammarström M, Hall P, Wengström Y, Broeders MJM, van der Waal D.Psychooncology. 2019 Mar 7. doi: 10.1002/pon.5051. [Epub ahead of print]

Modifiable risk factors for advanced versus early breast cancer in the French E3N cohort.
Veron L, et al. Int J Cancer. 2019 Apr 19. doi: 10.1002/ijc.32354.

A response to « Personalised medicine and population health: breast and ovarian cancer ».
Antoniou A, et al. Hum Genet. 2019 Mar;138(3):287-289. doi: 10.1007/s00439-019-01984-z. Epub 2019 Feb 27.

Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes.
Mavaddat N, et al.  Am J Hum Genet. 2019 Jan 3;104(1):21-34. doi: 10.1016/j.ajhg.2018.11.002. Epub 2018 Dec 13.

Genome-wide association study of germline variants and breast cancer-specific mortality.
Escala-Garcia M, et al. Br J Cancer. 2019 Mar;120(6):647-657. doi: 10.1038/s41416-019-0393-x. Epub 2019 Feb 21.

BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors.
Lee A, at al.Genet Med. 2019 Jan 15. doi: 10.1038/s41436-018-0406-9.

Prediction of reader estimates of mammographic density using convolutional neural networks.
Ionescu GV, et al. J Med Imaging (Bellingham). 2019 Jul;6(3):031405. doi: 10.1117/1.JMI.6.3.031405. Epub 2019 Jan 31.

A new automated method to evaluate 2D mammographic breast density according to BI-RADS® Atlas Fifth Edition recommendations.
Balleyguier C et al. Eur Radiol. 2019 Feb 15. doi: 10.1007/s00330-019-06016-y.

Annual mammography at age 45-49 years and biennial mammography at age 50-69 years: comparing performance measures in an organised screening setting.
Bucchi L, et al. Emilia-Romagna Region Workgroup for Mammography Screening Evaluation.Eur Radiol. 2019 Mar 18. doi: 10.1007/s00330-019-06050-w.

Comparing two visualization protocols for tomosynthesis in screening: specificity and sensitivity of slabs versus planes plus slabs.
Iotti V, et al. RETomo Working Group.Eur Radiol. 2019 Feb 8. do16.